Alloimmunization in transfused patients with constitutional anemias in Norway

Furuseth, May Tove; Alme, Charlotte; Garvik, Liv Jorunn; Hellebostad, Marit; Bechensteen, Anne Grete; Akkök, Çiğdem Akalın

doi:10.1016/j.transci.2021.103257

Cited by 4 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these studies 44% to 71% were sensitized by the transfused RBCs as shown by incompatible major cross‐match results 11,21 . In cats, an alloimmunization rate up to 25% 22,28 and in human medicine of 1.8% to 20% was described 29‐33 …”

Section: Discussionmentioning

confidence: 99%

“…11,21 In cats, an alloimmunization rate up to 25% 22,28 and in human medicine of 1.8% to 20% was described. [29][30][31][32][33] However, it is assumed that based on the frequency and timing of antibody testing in human medicine, only 1/3 of the alloantibodies formed are actually detected. 34 In human medicine the risk of alloimmunization is dependent on various factors; for example, infections, autoimmune diseases, or certain blood diseases, such as sickle cell anemia, can increase the risk of alloimmunization.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Alloimmunization in dogs after transfusion: A serial cross‐match study

Herter

Weingart

Merten

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Cross‐matching is performed to determine the serological compatibility of donor and recipient blood. Current guidelines recommend that cross‐matching should be performed in dogs when an initial transfusion was performed more than 4 days ago or when the transfusion history is unknown. Hypothesis Determination at what time point alloantibodies are detected in dogs after transfusion. The hypothesis was that dogs would form alloantibodies within 4 days after a transfusion. Animals Twenty‐one anemic dogs were transfused and monitored for at least 4 subsequent days. Exclusion criteria were persistent red blood cell (RBC) agglutination and a previous transfusion. Methods Prospective observational study. Cross‐matching was performed before the initial DEA 1‐compatible transfusion and on days 1, 2, 3, and 4 and if possible, between day 5 and 28, using the tube method without enhancement (major cross‐match, recipient controls); recipients were monitored for transfusion reactions. Results In 12/21 dogs a positive cross‐match (microscopic degree of agglutination [AD] 1+ to 2+) was observed within 4 days after the transfusion. In a nonlinear regression model, no significant association was detected between type of anemia (P = .41), RBC storage time (P = .44), immunosuppressive treatment (P = .75) nor transfusion volume (P = .70) and the occurrence of positive cross‐matches within 4 days after transfusion. Another 4 dogs developed a positive cross‐match (microscopic AD 1+ to 2+) after 6 to 13 days. Conclusions and Clinical Importance Because production of alloantibodies was detected as early as 1 day after transfusion, cross‐matching should be performed before every subsequent transfusion.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Alloimmunization in dogs after transfusion: A serial cross‐match study

Herter

Weingart

Merten

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Currently, the number of patients requiring regular and chronic care related to red blood cell transfusion is increasing, especially in patients with sickle cell anemia (SCA), beta-thalassemia major, other hemoglobinopathies, myelodysplastic syndrome (MDS), and moderately severe hypoplastic anemia (SHAH et al, 2018;YOUNESI et al, 2016). Long-term transfusion poses a series of complications and clinical problems, including transfusion-related adverse reactions, such as the risk of transfusion-transmitted infections (Hepatitis B, Hepatitis C, HIV, among others), non-hemolytic febrile transfusion reactions (NHTR), allergic reactions, and iron overload as a result of repeated transfusions, especially in thalassemia patients (FURUSETH et al, 2021;HINDAWI et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Importance of phenotyping in blood donors for the identification of rare phenotypes

Cardoso,

Vizzoni

2023

DS-CS

View full text Add to dashboard Cite

Introduction: Erythrocyte alloimmunization may arise from blood group incompatibility between ethnically diverse donors and recipients. Providing blood to patients with rare or complex red cell antigen profiles poses a significant challenge. These individuals may have red blood cells that either lack high incidence antigens or possess a combination of several uncommon antigens. As a result, finding compatible blood donors becomes difficult. Methods: The objective was to identify extended phenotyping strategies for the various blood group systems to aid transfusion in patients with a phenotype considered rare. This is a systematic review, in which parameters were followed as a basis for the PRISMA recommendations with a focus on the search for the literature published in the last 10 years on erythrocyte phenotyping in blood donors, aiming to identify rare phenotypes for transfusion support. Results: We found 20 articles describing rare antigens and antibodies, reporting difficulties in finding compatible blood and the need for a registry of these blood donors. In summary, the provision of blood to patients with red cells lacking high incidence antigens or complex antigen profiles is indeed a challenging task. It necessitates specialized testing, access to rare blood donors, and alternative strategies to ensure the best possible match for transfusion.

show abstract